Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Pacific Biosciences reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of +27.78% [1] - The company posted revenues of $39.77 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 9.06% and showing an increase from $36.01 million in the same quarter last year [2] - Over the last four quarters, Pacific Biosciences has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Pacific Biosciences shares have declined approximately 24.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $40.08 million, and for the current fiscal year, it is -$0.64 on revenues of $155.44 million [7] Industry Outlook - The Medical - Instruments industry, to which Pacific Biosciences belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact the stock's performance [5]